The combination of Semax and Selank is one of the most discussed pairings in peptide and nootropic research. Both peptides were developed in Russia and are often seen as complementary compounds as they affect different areas of brain function. Semax is primarily studied for cognitive function, memory, neuroprotection, and neuroplasticity, while Selank is analysed mainly in the context of anxiety regulation, stress resilience, emotional balance, and GABAergic signalling [1–8].
Owing to these differences, researchers are investigating whether combining Semax and Selank might offer broader neurological support than using either peptide individually. While the biological rationale for this approach appears compelling, direct clinical investigation into the simultaneous use of both peptides remains limited.
Co Robią Semax i Selank?
Although both peptides interact with the central nervous system, they appear to act via different biological pathways.
Semax is a synthetic peptide derived from the ACTH(4-10) fragment. Studies suggest it may influence learning processes, memory, attention, neuroprotection, and recovery from neurological damage. Experimental studies have shown that Semax can modulate dopamine and serotonin activity, increase brain-derived neurotrophic factor (BDNF) levels, regulate TrkB receptor activity, and affect genes associated with inflammation, immune response, and neuronal survival [9–15].
Selank, on the other hand, is a synthetic analogue of tuftsin, primarily studied for its anxiety-reducing and emotion-regulating properties. Research findings suggest it may act as a positive allosteric modulator of GABA receptors, inhibit enzymes responsible for enkephalin breakdown, influence BDNF expression, and modulate neurotransmitter systems associated with stress response and mood control [1–5]. Clinical studies have observed anxiolytic effects comparable to some conventional anxiolytic drugs with minimal sedative action [6].
Can Semax and Selank be combined?
One of the most frequently asked questions is the possibility of using Semax and Selank simultaneously.
From a biological perspective, such a combination appears interesting, as both peptides influence different but complementary systems in the brain. Semax is primarily associated with supporting cognitive functions, neuroplasticity, and neuroprotection, while Selank is more associated with stress regulation, emotional stability, and anxiety reduction [1-15].
Since their mechanisms of action do not appear to directly overlap, many researchers consider them to be complementary, rather than duplicating, peptides.
However, it should be emphasised that large-scale clinical trials directly evaluating the combination of Semax and Selank have not yet been published. Most discussions regarding this stack are based on the analysis of biological mechanisms, clinical observations, and user reports, rather than direct comparative studies.
Potential Benefits of Semax and Selank Stack
The potential benefits of combining Semax and Selank are linked to their different areas of biological activity.
Research into Semax indicates potential support for attention, memory formation, learning ability, mental performance, neuroplasticity, and neuroprotection. Numerous studies have demonstrated increased BDNF expression and activation of pathways related to neuronal survival and synaptic adaptation [10–15].
Research on Selank primarily focuses on anxiety reduction, emotional regulation, stress resilience, GABA signalling, and neuroimmunomodulation. Effects on enkephalin metabolism, BDNF regulation, and neurotransmitter systems associated with emotional stability and mood have also been demonstrated [1–6].
Due to these differences, Semax and Selank are often discussed as potential solutions to support cognitive performance and emotional well-being simultaneously.
Semax and Selank: Cognitive Functions and Concentration
One reason for interest in this combination is the fact that anxiety and chronic stress can negatively affect cognitive abilities. Semax has been studied for its potential to support learning, memory, and mental performance, while Selank has been analysed in the context of reducing anxiety and improving emotional balance [1–15].
Theoretically, simultaneously supporting cognitive function and stress regulation can create more favourable conditions for concentration, productivity, and mental efficiency. It is precisely this potential complementary effect that makes the combination of both peptides often discussed in nootropic and peptide communities.
Semax, Selank and Neuroplasticity
Both peptides are associated with neurotrophic signalling pathways, particularly those involving BDNF.
Experimental studies have shown that Semax can increase the expression of BDNF and TrkB receptors in brain regions responsible for learning and memory [10,11]. Separate studies have also shown that nasal administration of Selank can affect BDNF expression in the hippocampus [7].
As BDNF plays a key role in neuroplasticity, neuronal adaptation, learning processes, and memory formation, some researchers believe that the combined effect of Semax and Selank on these pathways may contribute to their nootropic potential. However, it should be emphasized that direct studies analysing the impact of combining both peptides on neuroplasticity remain limited.
Is the combination of Semax and Selank better than either peptide on its own?
Currently, there is no definitive scientific evidence to indicate that the combination of Semax and Selank is more effective than using either peptide individually.
For studies focusing primarily on memory, attention, learning, neuroprotection or neurological regeneration, Semax currently has stronger scientific backing. In contrast, for studies concerning anxiety, emotional regulation, stress resilience and mechanisms related to the GABA system, more data has been gathered for Selank [1–15].
The basis for interest in this combination is the ability to simultaneously support cognitive and emotional processes. However, further clinical trials involving humans are needed before drawing definitive conclusions.
What to Choose: Semax, Selank, or Both Peptides?
The answer depends primarily on the research objective.
If the main area of interest is cognitive functions, memory, concentration, learning, or neuroprotection, Semax is the peptide most frequently studied for these applications. If, on the other hand, the research goal is anxiety reduction, emotional balance, stress adaptation, or regulation of the GABAergic system, Selank is usually the preferred research peptide.
Researchers interested in both cognitive performance and emotional resilience often explore the possibility of combining the two peptides, as they appear to affect different neurobiological systems [1–15].
Instead of competing with each other, Semax and Selank are often seen as complementary peptides influencing different aspects of brain function.
Summary
Semax and Selank combine two of the most recognisable neuroactive peptides developed in Russia. Semax is primarily studied for cognitive function, neuroprotection, memory and neuroplasticity, while Selank is mainly analysed in the context of anxiety reduction, stress resilience and emotional regulation.
Current research suggests that both peptides act on different biological pathways and may provide complementary effects. However, direct clinical studies on the simultaneous use of Semax and Selank are still limited, hence further human studies are needed to determine whether such a combination offers an advantage over using each peptide separately.
Disclaimer
This article is for educational and informational purposes only. Semax and Selank are research peptides, and scientific knowledge regarding their mechanisms of action and long-term effects is constantly evolving. The information presented is a summary of published laboratory, preclinical, and clinical research findings and should not be interpreted as medical advice, therapeutic recommendation, or confirmation of efficacy.
For research purposes only: The Semax and Selank products offered by Semax Polska are intended solely for laboratory and scientific research. They are not authorised for human consumption or for use for medical, diagnostic, therapeutic or prophylactic purposes. All research materials should be used in accordance with applicable legislation and the guidelines of the institutions conducting scientific research.
References
[1] Vyunova, T. V., Andreeva, L., Shevchenko, K., & Myasoedov, N. (2018). Peptide-Based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters, 25(10), 914–923. https://doi.org/10.2174/0929866525666180925144642
[2] Zozulya, A. A., Kost, N. V., Sokolov, O. Y., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. N., Zolotarev, Y. A., Ivanov, S. V., Andryushchenko, A. V., Myasoedov, N. F., & Smulevich, A. B. (2001). The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes as a Possible Mechanism of Its Anxiolytic Activity. Bulletin of Experimental Biology and Medicine, 131(4), 315–317. https://doi.org/10.1023/A:1017979514274
[3] Kost, N. V., Sokolov, O. Y., Zozulya, S. A., & Myasoedov, N. F. (2025). Combined Action of Benzodiazepine Tranquillisers and Peptide Anxiolytic Selank in BALB/c Mice. Neurochemical Journal, 19, 743–748. https://doi.org/10.1134/S1819712425700783
[4] Czabak-Garbacz, R., Cygan, B., Wolański, Ł., & Kozlovsky, I. (2006). Influence of Long-Term Treatment with Tuftsin Analogue TP-7 on Anxiety-Phobic States and Body Weight. Pharmacological Reports, 58(4), 562–567. PMID: 16963804
[5] Zozulia, A. A., Neznamov, G. G., Siuniakov, T. S., Kost, N. V., Gabaeva, M. V., Sokolov, O. Y., Serebriakova, E. V., Siranchieva, O. A., Andriushenko, A. V., Telesheva, E. S., Siuniakov, S. A., Smulevich, A. B., Myasoedov, N. F., & Seredenin, S. B. (2008). Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalised Anxiety Disorders and Neurasthenia. Journal of Neurology and Psychiatry named after S.S. Korsakov, 108(4), 38–48. https://pubmed.ncbi.nlm.nih.gov/18454096/
[6] Levitskaya, N. G., Andreeva, L. A., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Intranasal Administration of the Peptide Selank Regulates BDNF Expression in the Rat Hippocampus In Vivo. Doklady Biological Sciences, 431, 79–82.
[7] Andreeva, L. A., Nagaev, I. Y., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Antiviral Properties of Structural Fragments of the Peptide Selank. Doklady Biological Sciences, 431, 79–82. https://doi.org/10.1134/S0012496610020031
[8] Monis, A., & Maple, K. (2024). Sermorelin is a synthetic peptide that mimics the action of growth hormone-releasing hormone (GHRH). It is used in medical settings, primarily for diagnostic purposes to assess growth hormone deficiency in children and adults. Medical evidence regarding sermorelin often focuses on its ability to stimulate the pituitary gland to release growth hormone. While it's not a direct growth hormone replacement, it's used to test the pituitary's responsiveness. **Key areas where medical evidence exists for sermorelin include:** * **Diagnosis of Growth Hormone Deficiency (GHD):** The cornerstone of sermorelin's medical use is as a provocative agent in diagnostic tests for GHD. By administering sermorelin and monitoring subsequent growth hormone levels, clinicians can determine if a patient's pituitary gland is capable of producing adequate growth hormone. This is especially relevant in pediatric endocrinology. * **Potential Therapeutic Uses (with caveats):** While not widely approved for general therapeutic use in adults for conditions like aging or muscle wasting, there has been research and some off-label use exploring sermorelin for: * **Body composition changes:** Some studies have investigated its effects on lean muscle mass and fat reduction, though results can be variable and it's not a primary treatment for obesity. * **Improved sleep and energy levels:** Anecdotal reports and some small studies suggest potential benefits in these areas, but robust clinical trials are limited. * **Wound healing:** Some research has explored its potential role in accelerating wound repair. **Important Considerations regarding medical evidence:** * **Regulatory Status:** In many countries, sermorelin is approved primarily for diagnostic purposes. Its use for therapeutic purposes, particularly for anti-ageing or performance enhancement, is often considered off-label and may not be supported by extensive, high-quality clinical trials. * **Efficacy vs. Growth Hormone Therapy:** It's crucial to distinguish between sermorelin's diagnostic role and direct growth hormone therapy. While it stimulates GH release, it's not the same as administering exogenous growth hormone. * **Research Limitations:** Much of the research on sermorelin for therapeutic applications is either preliminary, small-scale, or conducted outside of regulated clinical trial settings. Larger, well-controlled studies are often needed to confirm its efficacy and safety for various conditions. * **Side Effects:** Like any medication, sermorelin has potential side effects, which should be discussed with a healthcare professional. **In summary:** The most established medical evidence for sermorelin pertains to its diagnostic utility in identifying growth hormone deficiency. While research into its potential therapeutic benefits continues, these applications are generally less well-supported by extensive, high-quality clinical evidence compared to its diagnostic role.. White Paper: A Review of the Mechanisms and Neuroregulatory Pathways of Growth Hormone-Releasing Peptide.
[9] Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) Analogue with Nootropic Properties, Activates Dopaminergic and Serotonergic Brain Systems in Rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
[10] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Y., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax Regulates BDNF and TrkB Expression in the Rat Hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
[11] Dolotov, O. V., Karpenko, E. A., Seredenina, T. S., Inozemtseva, L. S., Levitskaya, N. G., Zolotarev, Y. A., Kamensky, A. A., Grivennikov, I. A., Engele, J., & Myasoedov, N. F. (2006). Semax binds specifically and increases BDNF protein levels in rat basal forebrain.. Journal of Neurochemistry, 97(Suppl. 1), 82–86. https://doi.org/10.1111/j.1471-4159.2006.03658.x
[12] Medvedeva, E. V., Dmitrieva, V. G., Povarova, O. V., Limborskaia, S. A., Skvortsova, V. I., Myasoedov, N. F., & Dergunova, L. V. (2014). The Peptide Semax Affects Expression of Genes Related to the Immune and Vascular Systems in Rat Brain Focal Ischaemia. BMC Genomics, 15, 228. https://doi.org/10.1186/1471-2164-15-228
[13] Medvedeva, E. V., Dmitrieva, V. G., Limborskaia, S. A., Myasoedov, N. F., & Dergunova, L. V. (2017). Semax Regulates Expression of Immune Response Genes during Ischemic Brain Injury in Rats. Molecular Genetics and Genomics, 292(3), 635–653. https://doi.org/10.1007/s00438-017-1297-1
[14] Sudarkina, O. Y., Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Valieva, L. V., Remizova, J. A., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborskaia, S. A., & Dergunova, L. V. (2021). Brain Protein Expression Profile Confirms the Protective Effect of Semax in Cerebral Ischemia-Reperfusion. International Journal of Molecular Sciences, 22(12), 6179. https://doi.org/10.3390/ijms22126179
[15] Gusev, E. I., Martynov, M. Y., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The Efficacy of Semax in Patients at Different Stages of Ischaemic Stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68